SNOA Valuation

Sonoma Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

3.596

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

SNOA Relative Valuation

SNOA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNOA is overvalued; if below, it's undervalued.

Historical Valuation

Sonoma Pharmaceuticals Inc (SNOA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.34 is considered Fairly compared with the five-year average of -0.88. The fair price of Sonoma Pharmaceuticals Inc (SNOA) is between 2.43 to 4.75 according to relative valuation methord.

Relative Value

Fair Zone

2.43-4.75

Current Price：3.60

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.37

P/B

Median3y

0.71

Median5y

1.11

-2.88

FCF Yield

Median3y

-92.52

Median5y

-69.30

Competitors Valuation Multiple

The average P/S ratio for SNOA's competitors is 0.46, providing a benchmark for relative valuation. Sonoma Pharmaceuticals Inc Corp (SNOA) exhibits a P/S ratio of 0.34, which is -26.38% above the industry average. Given its robust revenue growth of 9.16%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SNOA.O

Sonoma Pharmaceuticals Inc

0.34

Average P/S: 0.46

9.16%